FibroGen, Inc.


After the markets closed, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to the stratification factors. The company said it would conduct a “comprehensive internal review to ensure” that such errors do not occur again. In after hours trading, FibroGen’s shares are plunging by over 25%.

Lead Plaintiff deadline
class period
Case Documents
No documents available. Contact us if you need a case document.